Cardinal Health (NYSE:CAH) Stock

Cardinal Health

Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Cardinal Health Inc

CARRIER ALLIANCE HLDGS by Carrier Alliance Holdings, Inc.

Carrier Alliance Holdings Inc

CELESTIAL ASIA SECS NEW by Celestial Asia Secs Holdings Ltd.

Celestial Asia Securities Holdings Ltd

Caro Holdings Inc

EVOLUTION MINING LTD ORD by Evolution Mining Ltd.

Evolution Mining Ltd

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $166 to $181.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $181

Citigroup analyst Daniel Grosslight maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Neutral and raises the price target from $157 to $170.

Citigroup Maintains Neutral on Cardinal Health, Raises Price Target to $170

Evercore ISI Group analyst Elizabeth Anderson maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Outperform and raises the price target from $175 to $180.

Evercore ISI Group Maintains Outperform on Cardinal Health, Raises Price Target to $180

WIIM

Cardinal Health shares are trading higher after the company raised its FY25 guidance. '

Guidance

Cardinal Health Expecting At Least $10B In Total Adjusted Free Cash Flow Over Next 3-Years; Raising Baseline Share Repurchase Plans To At Least $750M Per Year

Cardinal Health Raises FY25 Non-GAAP Diluted EPS Guidance To $8.15 - $8.20

Preliminary fiscal year 2026 guidance The company is providing preliminary guidance for fiscal year 2026:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Non-GAAP diluted EPS</td>
<td colspan="1" rowspan="1">
$9.10 to $9.30
(+13% growth at mid-points)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted free cash flow</td>
<td colspan="1" rowspan="1">$2.75B to $3.25B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">~$600M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest and other</td>
<td colspan="1" rowspan="1">~$275M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP effective tax rate</td>
<td colspan="1" rowspan="1">22% to 24%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pharmaceutical and Specialty Solutions:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">11% to 13% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">10% to 12% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">5% to 7% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Global Medical Products and Distribution:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">3% to 5% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit</td>
<td colspan="1" rowspan="1">&nbsp;$140M+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other5:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Reported)</td>
<td colspan="1" rowspan="1">26% to 28% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">25% to 27% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Normalized)4</td>
<td colspan="1" rowspan="1">10% to 12% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">~10% growth</td>
</tr>
</tbody>
</table>
</figure>
Long-term targets The company is providing updated long-term targets (fiscal years 2026 to 2028 CAGRs3):
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Non-GAAP diluted EPS</td>
<td colspan="1" rowspan="1">12% to 14% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pharmaceutical and Specialty Solutions:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">8% to 10% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">7% to 9% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">5% to 7% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Global Medical Products and Distribution:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">2% to 4% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit</td>
<td colspan="1" rowspan="1">$50M+ of profit growth per year after FY26</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other5:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Reported)</td>
<td colspan="1" rowspan="1">16% to 18% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">15% to 17% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Normalized)4</td>
<td colspan="1" rowspan="1">10% to 12% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">~10% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp; Adjusted Free Cash Flow (FY26 to FY28 total)</td>
<td colspan="1" rowspan="1">At least $10B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp; Share Repurchases (FY26 to FY28 total)</td>
<td colspan="1" rowspan="1">At least $2.25B</td>
</tr>
</tbody>
</table>
</figure>

Cardinal Health Provides Preliminary FY26 Guidance With Non-GAAP EPS Of $9.10-$9.30, Adj. FCF Of $2.75B-$3.25B, Capital Expenditures ~$600M, Sees Segment Revenue Growth Across Key Divisions; Updates Long-Term Targets Through 2028 Including 12% - 14% EPS CAGR And Revenue Growth Across Key Divisions

BofA Securities analyst Allen Lutz reiterated the Buy rating on Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), <a target="_blank" href="https://www.benzinga.com/quote/CAH/analyst-ratings" rel="noreferrer noopener">raising the price forecast from $165 to $170.</a>
Lutz noted that Cardinal Health is set to host its investor day in New York on June 12, where the company will offer an updated business outlook compared to its last investor event two years ago.
With strong performance over the past two years and favorable industry dynamics—such as rising utilization and IRA-driven out-of-pocket cost changes—expectations are elevated.
Also Read: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45865665/trumps-inflation-honeymoon-may-be-over" target="_blank" rel="noreferrer noopener">Trump&#8217;s Inflation Honeymoon May Be Over</a>
Lutz anticipates that the company will lay out a roadmap toward sustained double-digit EPS growth and may also revise its Pharmaceutical and Specialty Solutions EBIT growth outlook upward.
Additionally, management is expected to share updates on its recent investments in specialty areas, including Specialty Networks and its MSO platform, and provide insight into future growth prospects and consolidation opportunities.
Lutz projects Cardinal Health to lift its long-term Pharmaceutical EBIT growth target from the current 4–6% range to 5–7% or possibly 5–8%, supported by both favorable industry conditions and internal execution. While investors have historically viewed Cardinal's pharma growth as lagging behind peers like McKesson (6–8% target) and Cencora (5–8% target), those views may be outdated.
According to Lutz, Cardinal's prior scale disadvantage in specialty is diminishing, and its relatively smaller size means that recent M&amp;A activity could have a more significant growth impact compared to larger competitors.
Lutz projects Cardinal Health to offer an updated perspective on the growth path of its Global Medical Products and Distribution segment during the investor day, including steps taken to offset tariff impacts, momentum in its branded product portfolio, evolving demand trends, and its position relative to competitors.
Growth in the company's Other segment has also been solid, and Lutz sees potential for sustained high-single-digit EBIT growth in that area. Additionally, the analyst anticipates Cardinal Health will continue maintaining a balanced capital allocation strategy, combining selective acquisitions, share buybacks, and ongoing debt reduction.
Price Action: CAH shares are trading higher by 0.42% to $153.72 at last check Wednesday.
Read now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45848820/stock-buybacks-are-quietly-powering-wall-streets-2025-rally" target="_blank" rel="noreferrer noopener">Stock Buybacks Are Quietly Powering Wall Street's 2025 Rally</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Equities

Markets

Trading Ideas

General

Cardinal Health Analyst Flags Fading Scale Gap, Sees Rising Edge in Specialty Growth

B of A Securities analyst Michael Cherny maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $165 to $170.

B of A Securities Maintains Buy on Cardinal Health, Raises Price Target to $170

CRANFORD, N.J., June 9, 2025 /PRNewswire/ --&nbsp;Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a distribution services agreement with Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), a leading provider of pharmaceutical and specialty pharmaceutical distribution services in the United States.
This agreement is designed to help provide access to LYMPHIR&#x2122; (denileukin diftitox-cxdl), an innovative immunotherapy FDA-approved for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), in support of its anticipated U.S. commercial launch.

CTOR

CTXR

Citius Pharma's Subsidiary Citius Oncology Enters Into Distribution Services Agreement With Cardinal Health; Deal Supports Upcoming Launch Of LYMPHIR For Treatment Of Cutaneous T-Cell Lymphoma

Cardinal Health Announced The U.S. Launch Of Its Multi-parameter, Single-patient Use Monitoring Cable And Lead Wire System That Enables The Continuous Monitoring Of Cardiac Activity, Blood Oxygen Level And Temperature With One Point Of Connection

Wells Fargo analyst Stephen Baxter upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Equal-Weight to Overweight and raises the price target from $136 to $179.

Upgrades

Wells Fargo Upgrades Cardinal Health to Overweight, Raises Price Target to $179

Cardinal Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) short percent of float has fallen 10.53% since its last report. The company recently reported that it has 5.33 million shares sold short, which is 2.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cardinal Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748361629_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cardinal Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cardinal Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cardinal Health's peer group average for short interest as a percentage of float is 4.46%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around Cardinal Health?

Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025 and is back with more than a dozen more trades less than two weeks after <a href="https://www.benzinga.com/politics/25/05/45272436/marjorie-taylor-greene-goes-stock-shopping-again-here-are-50-stocks-the-congresswoman-bought">her last disclosure.</a>
Here's the latest transactions made by the congresswoman in May.
What Happened: Greene ranks 24th among the <a href="https://www.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank">best-performing members</a> of Congress based on their trades in 2024. The Congresswoman gained 30.2% for the year, outperforming the S&amp;P 500 gain of 24.9%.
Greene recently disclosed over 50 new stock trades in early May, which came on top of some potentially perfectly timed trades that happened before President Donald Trump&#8217;s pause of tariffs, which sent the market soaring.
Here are Greene&#8217;s most recent trades made on May 14, per the <a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene" target="_blank" rel="noreferrer noopener">Benzinga Government Trades page</a>. All purchases made were listed as between $1,001 to $15,000 unless otherwise indicated.
<ul class="wp-block-list">
<li>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>): $15,000 to $50,000</li>
<li>Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</li>
<li>Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</li>
<li>Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</li>
<li>Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>)</li>
<li>Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>)</li>
<li>Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>)</li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</li>
<li>Impinj Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>)</li>
<li>MercadoLibre Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>): $15,000 to $50,000</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)</li>
<li>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>)</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
</ul>
Greene also disclosed buying an additional $1,000 to $15,000 in UnitedHealth stock on May 16. The Congresswoman also disclosed buying $100,000 to $250,000 in US Treasury Bills on May 16.
Greene has bought $2.82 million in stocks in 2025 according to <a href="https://www.quiverquant.com/congresstrading/politician/Marjorie%20Taylor%20Greene-G000596">data </a>from Quiver Quantitative with only $75,000 in stock sales. The Congresswoman bought $3.89 million in stocks in 2024 with $65,000 in sales.
Read Also: <a href="https://www.benzinga.com/politics/25/05/45449720/speaker-johnson-backs-congressional-stock-trading-ban-ruined-by-a-few-bad-actors">Speaker Johnson Backs Congressional Stock Trading Ban: Ruined By &#8216;A Few Bad Actors&#8217;</a>
Why It&#8217;s Important: Members of Congress are allowed to buy and sell stocks as long as they properly disclose the transaction.
The process has drawn scrutiny from the public and retail investors as members of Congress could have inside information and time their trades accordingly. Committee assignments in particular, often draw red flags from investors.
Greene serves on the House Committee on Oversight and Accountability and the House Committee on Homeland Security with several subcommittee appointments. The congresswoman&#8217;s past trade in technology and cybersecurity stocks has drawn attention with her role within Homeland Security.
Greene's past trades of Palantir Technologies and a<a href="https://www.benzinga.com/25/03/44255172/marjorie-taylor-greene-buys-more-bitcoin-etf-shares-ahead-of-trumps-strategic-reserve-executive-order" target="_blank" rel="noreferrer noopener">&nbsp;Bitcoin ETF&nbsp;</a>have drawn criticism along with the timing of her trades, as she is a close ally to President&nbsp;Donald Trump.
When asked previously about buying stocks earlier this year that soared days later after Trump announced a pause to tariffs, Greene<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noreferrer noopener">&nbsp;brushed aside the criticism.</a>
"I think that criticism is laughable. President Trump has been talking about tariffs for decades," Greene told reporters when asked about the trades at a recent town hall event in Georgia in a clip&nbsp;<a href="https://x.com/unusual_whales/status/1912456434081480777" target="_blank" rel="noreferrer noopener">shared&nbsp;</a>by Unusual Whales. The congresswoman used the opportunity to boast about her stock performance, which ranked her as one of the top trading members of Congress in 2024.
"I don't place my buys and sells,&#8221; Greene said, citing an agreement she has with her portfolio manager, who handles all the buying and selling of stocks. "He did a great job. Guess what he did. He bought the dip. And that's what anybody that has financial sense does.&#8221;
Greene also said her portfolio manager did not have inside information, everything was public and a potential tariff pause wasn't a secret.
Sen.&nbsp;Josh Hawley&nbsp;(R-Mo.) has reintroduced legislation that would ban members of Congress from trading or holding individual stocks.
The bill is known as the Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act based on the first letter of each of the main words. The name takes aim at the congresswoman and former Speaker of the House&nbsp;Nancy Pelosi&nbsp;(D-Calif.). &nbsp;
"Members of Congress should be fighting for the people they were elected to serve — not day trading at the expense of their constituents," Hawley&nbsp;<a href="https://www.hawley.senate.gov/hawley-reintroduces-pelosi-act-to-ban-congress-from-trading-stocks/" target="_blank" rel="noreferrer noopener">said</a>. "Americans have seen politician after politician turn a profit using information not available to the general public."
Hawley said the bill will help "restore Americans' trust in our nation's legislative body."
Hawley's bill is being reintroduced as President&nbsp;Donald Trump&nbsp;<a href="https://time.com/7280114/donald-trump-2025-interview-transcript/" target="_blank" rel="noreferrer noopener">said&nbsp;</a>he would support such a ban.
"Well, I watched Nancy Pelosi get rich through insider information, and I would be okay with it. If they send it to me, I would do it," Trump told TIME.
Trump said he would sign the ban if the bill passes Congress.
While Pelosi makes headlines for her trades, it's important to remember that<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noreferrer noopener">&nbsp;it is both Republican</a>&nbsp;and Democratic members of Congress who are profiting from buying and selling stocks and options while in office, with some trades coming with questionable timing or having a connection to committees they serve on.
In 2024, a list of the top-performing traders in Congress included six Republicans and four Democrats.
Did You Know?
<ul class="wp-block-list">
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent052025" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent052025"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20135920/Picture1-5-1024x330.png" alt="" class="wp-image-921773" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20135920/Picture1-5-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20135920/Picture1-5-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20135920/Picture1-5-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20135920/Picture1-5.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Image: Shutterstock

Politics

AMGN

GOOG

MELI

NFLX

NVDA

TSLA

Marjorie Taylor Greene Goes Shopping For Tesla, Netflix, UnitedHealth And More: 19 Stocks The Congresswoman Bought

<a href="https://www.cnbc.com/2025/05/12/trump-drug-pricing-order-most-favored-nation.html">https://www.cnbc.com/2025/05/12/trump-drug-pricing-order-most-favored-nation.html</a>
&nbsp;
<ul>
<li>President Donald Trump will revive a controversial policy that aims to slash drug costs by tying the amount the government pays for some medicines to lower prices abroad, White House officials said.</li>
<li>The order is a blow to the pharmaceutical industry, which is already bracing for Trump&#39;s planned tariffs on prescription drugs.</li>
<li>It is Trump&#39;s latest effort to try to rein in U.S. prescription drug prices, which are two to three times higher on average than those in other developed nations.</li>
</ul>
&nbsp;

MRNA

'Trump To Sign Order To Cut Some U.S. Drug Prices To Match Those Abroad' - CNBC

Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip"> during a market dip.</a>
Here's the latest transactions made by the congresswoman in early May.
What Happened: Greene was ranked as the 24th best-performing member of Congress based on their trades in 2024. The Congresswoman gained 30.2% for the year, <a href="https://www.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank">outperforming the S&amp;P 500 </a>gain of 24.9%.
With new trades placed throughout the early months of 2025, Greene could see huge returns again during the year.
Here are her most recent trades made on May 5, as shown on the <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725">Benzinga Government Trades page</a>. All purchases made were listed as between $1,001 to $15,000 unless otherwise indicated.
<ul>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</li>
<li>AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</li>
<li>Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)</li>
<li>Applied Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)</li>
<li>Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)</li>
<li>Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)</li>
<li>BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>)</li>
<li>BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>)</li>
<li>Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)</li>
<li>Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</li>
<li>Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
<li>Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</li>
<li>Cummins Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>)</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>)</li>
<li>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</li>
<li>Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)</li>
<li>Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>)</li>
<li>Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)</li>
<li>Frontline PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>)</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): two separate purchases of $1,001 to $15,000</li>
<li>Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>)</li>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)</li>
<li>Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>)</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</li>
<li>JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)</li>
<li>Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>)</li>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</li>
<li>MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>)</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Merck Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</li>
<li>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>)</li>
<li>ServiceNow Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>)</li>
<li>Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>): two separate purchases of $1,001 to $15,000</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>)</li>
<li>Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>): two separate purchases of $1,001 to $15,000</li>
<li>Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</li>
<li>Paychex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)</li>
<li>Impinj Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>)</li>
<li>Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)</li>
<li>Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>)</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</li>
<li>United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
<li>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</li>
<li>Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)</li>
</ul>
In total, that's more than 50 different stocks bought and disclosed by Greene in the latest filing. Based on the purchase range of $1,001 to $15,000, this would make the transaction range over $50,000 and up to more than $800,000.
Read Also: <a href="https://www.benzinga.com/politics/25/04/45077654/bill-named-after-nancy-pelosi-could-ban-congress-members-from-trading-stocks-what-you-need-to-know-about-the-pelosi-act">Bill Named After Nancy Pelosi Could Ban Congress Members From Trading Stocks: What You Need To Know About The &#8216;PELOSI&#8217; Act</a>
Why It's Important: Members of Congress are allowed to buy and sell stocks as long as they properly disclose the transaction.
The process has drawn scrutiny from the public and retail investors as members of Congress could have inside information and time their trades accordingly. Committee assignments in particular, often draw red flags from investors.
Greene serves on the House Committee on Oversight and Accountability and the House Committee on Homeland Security with several subcommittee appointments. The congresswoman's past trade in technology and cybersecurity stocks has drawn attention with her role within Homeland Security.
Greene&#8217;s past trades of Palantir Technologies and a<a href="https://www.benzinga.com/25/03/44255172/marjorie-taylor-greene-buys-more-bitcoin-etf-shares-ahead-of-trumps-strategic-reserve-executive-order"> Bitcoin ETF </a>have drawn criticism along with the timing of her trades, as she is a close ally to President Donald Trump. 
When asked previously about buying stocks earlier this year that soared days later after Trump announced a pause to tariffs, Greene<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip"> brushed aside the criticism.</a>
&#8220;I think that criticism is laughable. President Trump has been talking about tariffs for decades,&#8221; Greene told reporters when asked about the trades at a recent town hall event in Georgia in a clip <a href="https://x.com/unusual_whales/status/1912456434081480777" target="_blank" rel="noreferrer noopener">shared </a>by Unusual Whales. The congresswoman used the opportunity to boast about her stock performance, which ranked her as one of the top trading members of Congress in 2024.
&#8220;I don&#8217;t place my buys and sells," Greene said, citing an agreement she has with her portfolio manager, who handles all the buying and selling of stocks. &#8220;He did a great job. Guess what he did. He bought the dip. And that&#8217;s what anybody that has financial sense does."
Greene also said her portfolio manager did not have inside information, everything was public and a potential tariff pause wasn&#8217;t a secret.
Sen. Josh Hawley (R-Mo.) has reintroduced legislation that would ban members of Congress from trading or holding individual stocks.
The bill is known as the Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act based on the first letter of each of the main words. The name takes aim at the congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.).  
&#8220;Members of Congress should be fighting for the people they were elected to serve — not day trading at the expense of their constituents,&#8221; Hawley&nbsp;<a href="https://www.hawley.senate.gov/hawley-reintroduces-pelosi-act-to-ban-congress-from-trading-stocks/" target="_blank" rel="noreferrer noopener">said</a>. &#8220;Americans have seen politician after politician turn a profit using information not available to the general public.&#8221;
Hawley said the bill will help &#8220;restore Americans&#8217; trust in our nation&#8217;s legislative body.&#8221;
Hawley&#8217;s bill is being reintroduced as President&nbsp;Donald Trump&nbsp;<a href="https://time.com/7280114/donald-trump-2025-interview-transcript/" target="_blank" rel="noreferrer noopener">said&nbsp;</a>he would support such a ban.
&#8220;Well, I watched Nancy Pelosi get rich through insider information, and I would be okay with it. If they send it to me, I would do it,&#8221; Trump told TIME.
Trump said he would sign the ban if the bill passes Congress.
While Pelosi makes headlines for her trades, it&#8217;s important to remember that<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noreferrer noopener">&nbsp;it is both Republican</a>&nbsp;and Democratic members of Congress who are profiting from buying and selling stocks and options while in office, with some trades coming with questionable timing or having a connection to committees they serve on.
In 2024, a list of the top-performing traders in Congress included six Republicans and four Democrats.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-1024x330.png" alt="" class="wp-image-906796" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Photo: Shutterstock

Government

AAPL

ABBV

ADBE

AMAT

AMZN

DELL

GILD

INTC

MSFT

ODFL

PANW

PAYX

QCOM

SBUX

SCHW

Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought

<a href="https://www.washingtonpost.com/politics/2025/05/05/trump-presidency-news/#link-ACU42F27X5AMNOGEOOY7YDJOFE">https://www.washingtonpost.com/politics/2025/05/05/trump-presidency-news/#link-ACU42F27X5AMNOGEOOY7YDJOFE</a>
President Donald Trump will sign an executive order Monday to streamline regulations surrounding pharmaceutical manufacturing in the United States, according to two White House officials who spoke on the condition of anonymity to describe plans that have not been made public.
The order to incentivize domestic drug manufacturing comes ahead of possible <a href="https://www.washingtonpost.com/business/2025/04/10/tariffs-pharmaceuticals-us-drugs-cost/">tariffs on pharmaceuticals</a> — a policy that's on hold, for now, pending an investigation by the Commerce Department to determine whether importing pharmaceuticals is a threat to national security. That Section 232 investigation could be completed this summer, one of the officials said Monday.
But regardless of whether the Trump administration puts tariffs on prescription drugs, Monday's executive order seeks to incentivize more domestic manufacturing of medications.

Biotech

BNTX

'Trump To Sign Order To Encourage Domestic Drug Manufacturing' - Washington Post

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $142 to $166.

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $166

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $160 to $170.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $170

Baird analyst Eric Coldwell maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Outperform and raises the price target from $156 to $170.

Baird Maintains Outperform on Cardinal Health, Raises Price Target to $170

Health Care

Press Releases

Telix Announces Cardinal Health for Gozellix Commercial Distribution

Earnings

Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

Dividends

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health releases new report on the cell and gene therapy industry

Carlisle Companies Announces Leadership Appointments

Cardinal Health launches new medical device for the continuous monitoring of three essential vital signs in one system

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Cardinal Health Details Momentum and Updated Long-Term Value Creation Plans at Investor Day

Insurance

NYSE Content Advisory: Pre-Market update + Voyager, Ategrity pop double digits in debuts

Comments

Cardinal Health

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL